Menu
Not yet recruiting NCT07495605

Effect of 1% Melatonin Gel Versus Calcium Hydroxide as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp.

No phase Interventional Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 1% melatonin gel, Calcium Hydroxide (Ca(OH)2).
Who it may be relevant to
Registry conditions: Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp. Basic parameters: 21 years — 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effect of 1% Melatonin Gel Versus Calcium Hydroxide as an Intracanal Medicament on the Intensity of Postoperative Pain, Bacterial Load Reduction and Periapical MMP-9 Levels in Patients With Necrotic Pulp: A Randomized Clinical Trial

Overview

To compare the effect of 1% melatonin gel versus calcium hydroxide as intra canal medication in necrotic mandibular premolars on: * Intensity of postoperative pain. * Bacterial load reduction. * Periapical (MMP-9) level.

Interventions

  • Drug 1% melatonin gel
    1% melatonin gel: was prepared in the Drug Manufacture Unit, Faculty of Pharmacy, Cairo university
  • Drug Calcium Hydroxide (Ca(OH)2)
    a water-soluble, premixed calcium hydroxide paste with barium sulfate, supplied in a 2.2g syringe

Primary outcome measures

  • Intensity of postoperative pain [Time frame: up to 48 hours]
Secondary outcome measures (2)
  • Bacterial load reduction [Time frame: intraoperative]
  • Periapical MMP-9 level [Time frame: intraoperative]

Eligibility criteria

Inclusion criteria

  • Age between 18-50 years old.
  • Males and females.
  • Healthy patients categorized as I or II according to The American Society of Anesthesiologists. (ASA I or II), with no underlying allergies.
  • Single-rooted mandibular premolar teeth, having single root canal: diagnosed clinically with pulp necrosis.
  • Patients accepting to participate in the trial.
  • Patients who can understand pain scale (Appendix I) and can sign the informed consent (Appendix II).

Exclusion criteria

  • Medically compromised patients having significant systemic disorders (ASA III or IV).
  • Pregnant females.
  • If analgesics or antibiotics have been administrated by the patient during the past 24 hours preoperatively as it might alter their pain perception.
  • Teeth with multiple canals.
  • Teeth that show association with acute periapical abscess or swelling.
  • Teeth with vital pulp.
  • Non-restorable teeth or teeth that could not be adequately isolated with a rubber dam.
  • Immature teeth.
  • Teeth with greater than grade I mobility or pocket depth greater than 4 mm.
  • Teeth showing radiographic evidence of external or internal root resorption, vertical root fracture, perforation or calcification.
  • Patients with two or more adjacent teeth requiring endodontic treatment.
  • Patients reporting bruxism, clenching or TMJ problems.
  • Teeth with previous endodontic treatment.
  • Inability to perceive the given instructions.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07495605 · New Endo 3.3.3

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗